Sökning: onr:"swepub:oai:DiVA.org:uu-322680" >
Nodular lymphocyte ...
-
Molin, Daniel,1969-Uppsala universitet,Experimentell och klinisk onkologi
(författare)
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : an analysis of the Swedish Lymphoma Registry
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
2017-02-24
-
WILEY,2017
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-322680
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-322680URI
-
https://doi.org/10.1111/bjh.14567DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:135701144URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20(+) lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N=158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44years, respectively (P=0002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P=0033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P<000005), as did 10-year survival, 53% vs. 72% (multivariate P=0027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Linderoth, JohanLund Univ Hosp, Dept Oncol, Lund, Sweden.
(författare)
-
Wahlin, Björn E.Karolinska Institutet
(författare)
-
Uppsala universitetExperimentell och klinisk onkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:British Journal of Haematology: WILEY177:3, s. 449-4560007-10481365-2141
Internetlänk
Hitta via bibliotek
Till lärosätets databas